Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Drug Name

XPOVIO® (selinexor)

Developer

Karyopharm Therapeutics

Therapy Class

Nuclear export inhibitor

Product Description

Oral tablets

Current Indication

Diffuse large b-cell lymphoma (DLBCL)

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top